Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Literature
1.
Lauschke J, Maisch B (2009) Athlete’s heart or hypertrophic cardiomyopathy? Clin Res Cardiol 98:80–88PubMedCrossRef
2.
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED (2003) ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. Eur Heart J 24:1965–1991; J Am Coll Cardiol 42:1687–1713
3.
Maron BJ (2007) Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. Cardiol Clin 25:399–414PubMedCrossRef
4.
Kuhn H, Gietzen F (1999) Hypertrophische Kardiomyopathien. In: Daniel WG (ed) Thiemes Innere Medizin. 5 Kardiologie. Thieme Verlag Stuttgart, New York, pp 1211–1225
5.
Kuhn H, Mercier J, Köhler E, Frenzel H, Hort W, Loogen F (1983) Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy. Eur Heart J 4(Suppl F):93–104PubMed
6.
7.
Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H (2002) Fabry disease in patients with hypertrophic cardiomyopathy. Z Kardiol 91:992–1002PubMedCrossRef
8.
Gietzen FH, Leuner CJ, Obergassel L, Strunk-Müller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III or IV and outflow obstruction only under provocable conditions. Circulation 106:454–4595PubMedCrossRef
9.
Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C (2008) Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 97:234–243PubMedCrossRef
10.
Elliott PM, Gimeno JR, Tomè MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27:1933–1941PubMedCrossRef
Metadata
Title
On Lauschke J, Maisch B (2009): athlete’s heart or hypertrophic cardiomyopathy?
Author
Horst Kuhn
Publication date
01-07-2009
Publisher
D. Steinkopff-Verlag
Published in
Clinical Research in Cardiology / Issue 7/2009
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-009-0029-x

Other articles of this Issue 7/2009

Clinical Research in Cardiology 7/2009 Go to the issue

Original Paper

The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics

Clinical trial updates and hotline sessions

Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009

Clinical Correspondence

Interventional closure of two fistulas after aortic valve surgery

Clinical Correspondence

Iatrogenic epinephrine-induced reverse Takotsubo cardiomyopathy: direct evidence supporting the role of catecholamines in the pathophysiology of the “broken heart syndrome”

Letter to the Editors

Pitfalls in the differentiation between athlete’s heart and hypertrophic cardiomyopathy

Original Paper

Chronic total coronary occlusions in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits